Heterogeneity of Glucocorticoid Resistance in Patients with Bronchial Asthma

Bronchial asthma is assumed to be the result of excessive inflammation driven by an aberrant T-helper-2 (Th2) response. Recently, it has begun to be recognized that asthma is a heterogeneous disorder. Glucocorticoids (GCs) are effective treatment for bronchial asthma; however, the inflammation in br...

Descripción completa

Detalles Bibliográficos
Autor principal: Matsumura, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Master Publishing Group 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615268/
https://www.ncbi.nlm.nih.gov/pubmed/23675190
Descripción
Sumario:Bronchial asthma is assumed to be the result of excessive inflammation driven by an aberrant T-helper-2 (Th2) response. Recently, it has begun to be recognized that asthma is a heterogeneous disorder. Glucocorticoids (GCs) are effective treatment for bronchial asthma; however, the inflammation in bronchial asthma cannot always be fully controlled. A recent study demonstrated a new underlying mechanism of glucocorticoid resistance that acts in a Th2-independent manner. Thus, responses to GCs are highly heterogeneous.

Ejemplares similares